High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer.

High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer.

Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype of this disease. Targeted treatment has improved outcome, but there is still a need for new therapeutic strategies as some patients respond poorly to treatment. Our aim was to identify compounds that sub...

Fuld beskrivelse

Bibliografiske detaljer
Main Authors: Lisa Svartdal Normann, Mads Haugland Haugen, Vesa Hongisto, Miriam Ragle Aure, Suvi-Katri Leivonen, Vessela N Kristensen, Andliena Tahiri, Olav Engebraaten, Kristine Kleivi Sahlberg, Gunhild Mari Mælandsmo
Format: Article
Sprog:English
Udgivet: Public Library of Science (PLoS) 2023-01-01
Serier:PLoS ONE
Online adgang:https://doi.org/10.1371/journal.pone.0280507

Internet

https://doi.org/10.1371/journal.pone.0280507

Lignende værker